Back to results
US 2020/0368327 A1Published application
Methods for preparing modified von willebrand factor
AssigneeCsl Behring Lengnau AG
InventorsStefan SCHULTE, Hans-Wilhelm BELTZ, Sabine PESTEL, Thomas WEIMER, Matthias PELZING
Life of this patent
Estimating the term…
Abstract
The present invention provides modified von Willebrand Factor molecules, methods for their preparation and uses thereof. The invention further provides pharmaceutical compositions for treating coagulation disorders.
Claims15
-21. (canceled)
A method of treating a blood coagulation disorder, comprising administering to a subject in need thereof an effective amount of a glycoprotein and an effective amount of a Factor VIII (FVIII),
- wherein the glycoprotein comprises a truncated von Willebrand Factor (VWF) capable of binding to the FVIII,
- wherein the glycoprotein comprises N-glycans, wherein i) at least 75% of the N-glycans comprise at least one sialic acid moiety, ii) less than 35% of the N-glycans comprise two or more terminal and non-sialylated galactose residues, and/or iii) less than 6% of the N-glycans comprise three or more terminal and non-sialylated galactose residues,
- wherein the glycoprotein is administered intravenously or subcutaneously, and
- wherein the FVIII is administered intravenously or subcutaneously.
1 more element
Dependencies are inferred from the claim text.